Edward Chung
Head of Investor Relations
Replay available
Bio-Rad Laboratories, Inc. (NYSE: BIO) Q4 2021 earnings conference call, held 2022-02-10. Replay captured from the company's public earnings webcast.

Head of Investor Relations
Executive Vice President and Chief Financial Officer
Executive Vice President and Chief Operating Officer
President, Life Science Group
Chief Executive Officer
Analyst, Jefferies
Analyst, Wells Fargo
Analyst, Nephron Research
Good evening. Thank you for attending today's Bio-Rad Laboratories Q4 and full year financial results conference call. My name is Hannah and I will be your moderator for today's call. All lines will be muted during the presentation portion of the call with an opportunity for questions and answers at the end. If you would like to ask a question, please press star one on your telephone keypad. I would now like to pass the conference over to our host, Edward Chung, Head of Investor Relations with Bio-Rad. Please go ahead. Thanks, Hannah. Good afternoon and thank you all for joining us. Today, we will review the fourth quarter and full year 2021 financial results and provide an update on key business trends for Bio-Rad. With me on the phone today are Norman Schwartz, our Chief Executive Officer, Ilan Daskal, Executive Vice President and Chief Financial Officer, Andy Last, Executive Vice President and Chief Operating Officer, Simon May, President of the Life Science Group, and Dara Wright, President of the Clinical Diagnostics Group. Before we begin our review, I would like to caution everyone that we will be making forward-looking statements about management's goals, plans and expectations, our future financial performance, and other matters. These statements are based on assumptions and expectations of future events that are subject to risk and uncertainties. Included in these forward-looking statements are commentary regarding the impact of the COVID-19 pandemic on Bio-Rad's results and operations and steps Bio-Rad is taking in response to the pandemic. Our actual results may differ materially from these plans and expectations, and the impact and duration of the COVID-19 pandemic is unknown. You should not place undue reliance on these forward-looking statements, and I...